Quality of requests for serum digoxin concentrations: Experience from an Australian Regional Health Service

British Journal of Clinical Pharmacology

Volumn 63, Issue 5, 2007, Pages 623-627

  Ellington, Chris ^a   Grgurinovich, Nick ^b   Miners, John O ^a   Mangoni, Arduino A ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Digoxin; Monitoring; Quality of health care services

Indexed keywords

DIGOXIN;

ARTICLE; BLOOD SAMPLING; CORONARY CARE UNIT; DATA ANALYSIS; DIGOXIN BLOOD LEVEL; DRUG MONITORING; DRUG QUALITY; EMERGENCY WARD; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH SERVICE; INFORMATION PROCESSING; INTENSIVE CARE; MEDICAL AUDIT; MEDICAL PRACTICE; MEDICINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ANTI-ARRHYTHMIA AGENTS; CARDIOTONIC AGENTS; DIGOXIN; DRUG MONITORING; FAMILY PRACTICE; HOSPITALS; HUMANS; INTERDISCIPLINARY COMMUNICATION; MEDICAL AUDIT; QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES; SOUTH AUSTRALIA; SPECIALTIES, MEDICAL;

EID: 34247362491     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02802.x     Document Type: Article

References (15)

1. Medicare Australia. Pharmaceutical Benefits Schedule Item Statistics. Available at http://www.medicareaustralia.gov.au/statistics/dyn_pbs/forms/ pbs_tab1shtml 2006. Last accessed 5 May 2006.
2. Gheorghiade M, Adams KF Jr., Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation 2004 109 : 2959 64.
3. Horn JR, Christensen DB, deBlaquiere PA. Evaluation of a digoxin pharmacokinetic monitoring service in a community hospital. Drug Intell Clin Pharm 1985 19 : 45 52.
4. Duhme DW, Greenblatt DJ, Koch-Weser J. Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program. Ann Intern Med 1974 80 : 516 9.
5. Campbell TJ, Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol 2001 52 (Suppl. 1 21S 34S.
6. Sidwell A, Barclay M, Begg E, Moore G. Digoxin therapeutic drug monitoring: an audit and review. NZ Med J 2003 116 : U708.
7. Gibb I, Cowan JC, Parnham AJ, Thomas TH. Use and misuse of a digoxin assay service. BMJ (Clin Res Ed) 1986 293 : 678 80.
8. Kumana CR, Chan YM, Kou M. Audit exposes flawed blood sampling for 'digoxin levels'. Ther Drug Monit 1992 14 : 155 8.
9. Clague HW, Twum-Barima Y, Carruthers SG. An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls. Ther Drug Monit 1983 5 : 249 54.
10. Makela EH, Davis SK, Piveral K, Miller WA, Pleasants RA, Gadsden RHSr, Leman RB. Effect of data collection method on results of serum digoxin concentration audit. Am J Hosp Pharm 1988 45 : 126 30.
11. Smith J, Osikowicz G. Abbott AxSYM random and continuous access immunoassay system for improved workflow in the clinical laboratory. Clin Chem 1993 39 : 2063 9.
12. Schentag JJ, Bang AJ, Kozinski-Tober JL. Applied Pharmacokinetics and Pharmacodynamics. Philadelphia : Lippincott Williams & Wilkins 2006.
13. Soumerai SB, Avorn J. Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. Milbank Mem Fund Q Health Soc 1984 62 : 447 74.
14. Bates DW, Soldin SJ, Rainey PM, Micelli JN. Strategies for physician education in therapeutic drug monitoring. Clin Chem 1998 44 : 401 7.
15. Chen P, Tanasijevic MJ, Schoenenberger RA, Fiskio J, Kuperman GJ, Bates DW. A computer-based intervention for improving the appropriateness of antiepileptic drug level monitoring. Am J Clin Pathol 2003 119 : 432 8.